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Abstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors have shown great po-
tential in efficient lipid lowering to achieve low-density lipoprotein-cholesterol (LDL-C) treatment goals. 
The aim of the study was too describe the clinical use of PCSK9-inhibitors and to investigate therapy 
adherence and safety outside of clinical trials. 
Methods: Thirty-eight patients were treated with PSCK9-inhibitors. Patients were eligible for this 
therapy based on their individual cardiovascular risk and when all other available lipid-lowering regi-
men had failed. Every patient answered a questionnaire concerning medical history and relevant side 
effects and therapy adherence.
Results: Conventional therapy reduced patient LDL-C levels by about 38%. However, in 26 of the  
38 patients, LDL-C treatment goals were not fulfilled because patients did not tolerate further dose es-
calation due to side effects. Using a PCSK9 inhibitor, LDL-C levels were reduced by another 54% and 
42% of patients reaching treatment goals. The results show that most patients still require concomitant 
therapy to reach LDL-C target levels. Three patients required dose reduction or change of the PCSK9 
inhibitor. 16% did not inject the PCSK9 inhibitor regularly. 
Conclusions: Only a minority of patients reached the recommended LDL-C goals. PCSK9-inhibitors 
were generally well tolerated. Despite low rates of reported side effects, therapy adherence was incom-
plete, with 6 patients not injecting PCSK9-inhibitors on a regular basis. In-depth information about 
the medication and close supervision is advisable. PCSK9 inhibitors have shown great potential in 
aggressive lipid lowering therapy, but basic therapy is still required in most cases. Close supervision is 
recommended to improve therapy adherence. (Cardiol J 2018; 25, 1: 32–41)
Key words: cardiovascular risk, lipid lowering therapy, PCSK9-inhibitors, prevention, 
therapy adherence
Introduction
Cardiovascular disease burden
Cardiovascular disease (CVD) remains the 
most common cause of death world-wide. The 
Global Burden of Disease Study, published in 2013, 
estimates the total number of coronary artery 
disease (CAD)-related deaths at 17.3 million per 
year, accounting for 31.5% of all deaths and for 45% 
of all non-communicable deaths [1]. According to 
‘Cardiovascular disease in Europe: epidemiological 
update 2016’, CVD causes over 4 million deaths 
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per year, 1.4 million deaths occurring in patients 
younger than 75 years. The number of cardiovascu-
lar deaths in women (2.2 million or 49%) is slightly 
higher than in men (1.8 million or 40%) [2]. 
Low-density lipoprotein cholesterol as 
a causal factor for cardiovascular disease
The INTERHEART study (2004) character-
ized the effect of potentially modifiable risks for 
myocardial infarction in 52 countries [3]. Factors 
elevating cardiovascular risk were current or 
previous smoking, diabetes mellitus, elevated low-
density lipoprotein cholesterol (LDL-C), hyperten-
sion, abdominal obesity, irregular consumption of 
fruit and vegetables, lack of moderate alcohol con-
sumption and increased psychosocial stress. The 
presence of multiple risk factors led to an increased 
global cardiovascular risk and to the concept of 
a multi-modular intervention strategy to effectively 
reduce the risk for myocardial infarction.
Numerous studies over the last decades have 
demonstrated a causal relationship between LDL-C 
concentration and manifestation or progression of 
atherosclerosis and CVD. Experimental studies on 
the initiation of atherosclerosis, results from mo-
lecular and Mendelian randomization studies [4], 
and studies of familial hypercholesterolemia [5] 
firmly support this concept. Pharmacological 
inhibition of hepatic cholesterol synthesis or intes-
tinal cholesterol resorption depletes intracellular 
hepatic cholesterol, leading to increased expres-
sion of the hepatic LDL-C receptor and increased 
LDL-C plasma clearance. Large randomized 
controlled studies using statins as inhibitors of 
HMG-CoA-reductase [6], and ezetimibe as inhibi-
tors of NPLC1L1 [7] unanimously demonstrated 
a decrease of cardiovascular events. The long-term 
follow-up of LDL-C lowering therapy shows that 
cardiovascular outcome even after termination of 
the active intervention phase is improved (legacy 
effect) [8]. 
A recent review summarizing the efficacy and 
safety of statin therapy estimated that a reduction 
of LDL-C by 1 mmol/L results in about a 25% 
reduction in the rate of vascular events (defined 
as coronary death, myocardial infarction, stroke 
and coronary revascularization). Furthermore, 
a reduction by 2 mmol/L reduces the rate of car-
diovascular events of approximately 45%. In other 
words, treating 10,000 high-risk patients over a pe-
riod of 5 years would result in about 1,000 fewer 
vascular events [9]. Simultaneously, no effects of 
statin therapy on non-vascular events and death 
were found.
ESC/EAS Guidelines 2016 
In 2016, the European Society of Cardiology 
(ESC) together with the European Atherosclerosis 
Society (EAS) published comprehensive guidelines 
for the prevention of CVD and for the treatment 
of dyslipidemia [10, 11]. These guidelines rely on 
an individual estimation of global cardiovascular 
risk, and grade the recommended intensity of 
LDL-C lowering therapy according to four distinct 
risk categories. The very high risk group includes 
patients with documented CVD or cerebrovascular 
disease, aortic aneurysm, peripheral artery disease 
or significant plaque burden, patients with diabetes 
mellitus with target organ damage or an additional 
major risk factor and severe chronic kidney disease 
(defined as eGFR < 30 mL/min/1.73 m2). The high 
risk group includes patients with elevated single 
risk factors such as familial hypercholesterolemia, 
diabetes mellitus without additional major risk fac-
tors, and moderate chronic kidney disease (eGFR 
30–59 mL/min/1.73 m2). The guidelines recom-
mend a LDL-C goal < 70 mg/dL or a reduction 
of at least 50% if the baseline is between 70 and 
135 mg/dL for the very high-risk group, and 
a LDL-C goal < 100 mg/dL or a reduction of 
at least 50% if the baseline is between 100 and 
200 mg/dL for the high-risk group.
PCSK9 inhibitors as a new class  
of cholesterol lowering drugs
Proprotein convertase subtilisin/kexin type 9 
(PCSK9) is a serine protease involved in choles-
terol homeostasis. PCSK9 binds to the complex 
LDL-receptor inducing intracellular degradation, 
thereby reducing serum LDL clearance. The 
subcutaneously injected monoclonal antibodies di-
rected against PCSK9, alirocumab and evolocumab 
are approved by The Food and Drug Administration 
and European Medicines Agency for the treatment 
of hypercholesterolemia in patients with intoler-
ance or inadequate response to statins, especially 
for secondary prevention in a very high-risk situa-
tion or in the case of familial hypercholesterolemia. 
PCSK9 inhibition enables more efficient hepatic 
uptake of LDL and in most cases, decreases se-
rum LDL levels by > 50%, showing that PCSK9 
inhibition is an innovative therapeutic approach to 
improve control of elevated LDL-C levels. 
In October 2016, the ESC and the EAS Task 
Force published a consensus statement discussing 
the appropriate clinical use of PCSK9 antibodies 
in patients at very high cardiovascular risk who 
have substantially elevated LDL-C levels despite 
maximal statin/ezetimibe therapy [12].
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Methods
Thirty-eight patients from the lipid outpa-
tient clinic of the Hanover Medical School that had 
been treated with a PCSK9 inhibitor (alirocumab 
75/150 mg or evolocumab 140 mg) until present 
were retrospectively analyzed. Patients were classi-
fied as high risk or very high risk according to ESC 
guidelines of dyslipidemia, 2016 [11]. The LDL-C 
goals were as follows:
 — high risk — LDL-C < 100 mg/dL;
 — very high risk — LDL-C < 70 mg/dL.
Until 2016, PCSK9 treatment was begun if 
patients did not reach their LDL-C treatment goal 
under maximum tolerated lipid lowering therapy 
(e.g. statin, ezetimibe, colesevelam) or did not 
tolerate dose escalation due to side effects. After 
publication of the consensus statement from the 
ESC/EAS [12] we initiated PCSK9 treatment in 
very high-risk patients according to ESC guidelines 
[11] exhibiting LDL-C level > 140 mg/dL or in 
patients suffering from a progredient CVD who had 
LDL-C levels above 100 mg/dL. Patients in a high 
risk situation without evidence of CVD were also 
treated with a PCSK 9 inhibitor if they had LDL-C 
levels above 175 mg/dL and further cardiovascular 
risk factors. 
Genetic testing was performed sequentially: 
1. Sequencing of the entire LDL receptor;
2. If 1. was negative, sequencing of ApoB100 
gene;
3. If all of the above were negative, sequencing 
of the PCSK9 gene.
Positive family history was defined as a pre-
mature CAD or cerebrovascular event in women 
< 60 years and men < 55 years of age (in patients 
or first-degree relatives).
The Dutch Lipid Clinic Network was used for 
diagnostic criteria for familial hypercholesterine-
mia [5, 13, 14].
Lipid electrophoresis was performed using 
Hydragel 54 LDL/HDL CHOL Direct (Sebia). 
Lipoprotein(a) [Lp(a)] measurement was performed 
with Tina-quant® Lipoprotein (a) Gen. 2 (Cobas). 
Relevant Lp(a) elevation was defined as Lp(a) 
levels > 60 mg/dL or 150 nmol/L [15, 16]. 
All patients were asked to fill out a question-
naire on a voluntary basis concerning their history 
of CVD and experience with PCSK9 inhibitor treat-
ment (Supplemental Figure 1). Demographic 
characteristics, laboratory results, and results from 
genetic testing for mutations in the LDL-receptor, 
ApoB gene or PCSK9 gene were extracted from our 
lipid outpatient clinic database. Statistical analysis 
was performed with Microsoft Excel® using t-test 
without pretesting [17, 18]. SDAPS 1.9.4 was used 
to create and analyze the questionnaires. This 
study was approved by the local ethics commit-
tee (Ethics committee Hannover Medical School 
# 3471-2017).
Results
As of June 2017 38 high risk and very high-risk 
cardiovascular patients were treated with PCSK9 
inhibitors, either alirocumab (n = 19) or evolocum-
ab (n = 19). 18 patients were male and 20 were 
female (Table 1). One patient was lost to follow up 
after initiation of PCSK9 therapy. The average age 
was 59.7 years. The baseline LDL-C level from 
all patients was about 260 mg/dL. Five patients 
had both increased LDL-C levels and significantly 
increased Lp(a) elevation (> 150 nmol/L). The 
2 patients of the high-risk category had a target 
range for LDL-C of < 100 mg/dL. The 36 very 
high-risk patients had a target range for LDL-C of 
< 70 mg/dL. During first contact with patients we 
were able to work out a positive family history of 
myocardial infarction or ischemic stroke in about 
half of the patients. 23 patients gave consent for 
genetic testing for familial hypercholesterinemia, 
of which 17 had genetic alterations in the LDL 
receptor. Six of the patients did not exhibit any 
genetic abnormalities.
After admission to the lipid outpatient clinic, 
patients were initially treated with statins, co-
lesevelam, or ezetimibe-based therapies. Only 
5 patients out of 38 patients were treated with maxi- 
mum doses of (atorvastatin 80 mg, ezetimibe 10 mg 
or colesevelam 625 mg 6 × daily) (Table 2). Even 
after changing the initial medication to other lipid-
lowering drugs, only 12 patients had a combination 
therapy of ezetimibe and a statin in their respec-
tive maximum dosage. In the remaining patients, 
escalation to maximum dose was not achieved due 
to side effects such as statin-associated muscle 
symptoms or other symptoms such as articular 
pain and/or dizziness. In total, only 14 of 38 patients 
reached the allowed maximum dosage of the newly 
introduced statin (for example atorvastatin 80 mg, 
fluvastatin 80 mg, simvastatin 40 mg, rosuvastatin 
40 mg or pravastatin 40 mg). Five patients were 
on a therapy without any statin (such as ezetimibe 
or colesevelam). Utilizing different combinations 
of these drugs, average LDL-C levels were able to 
be reduced by about 38% (Fig. 1)
By adding a PCSK9 inhibitor the LDL-C levels 
were able to be reduced by another 54% (Fig. 1). In 
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Table 1. Patient characteristics: 38 patients (18 male and 20 female) from the documented outpatient 
lipid clinic were retrospectively analyzed. 36 out of 38 patients had documented coronary artery dis-
ease (CAD). 22/38 patients had a family history of CAD and 5/38 patients an elevation of lipoprotein(a) 
[Lp(a)]. Median age was 59.7 years.
Patient Sex Age FH Disease Lp(a) [nmol/L (mg/dL)] Elevation
1 M 42 Pos. 3-vessel CAD, MI, stenting 24 (10) No
2 F 65 Neg. AC plaque, aortic sclerosis 288 (120) Yes
3 F 76 Pos. ACI plaque 12 (5) No
4 F 70 Neg. 2-vessel CAD, PAD, stenting 143 (60) No
5 F 70 Neg. 3-vessel CAD, MI, stenting NA NA
6 M 56 Neg. MI 17 (7) No
7 F 72 Neg. ACI stenosis, 3-vessel CAD, CABG, PAD 137 (57) No
8 F 52 Pos. AC plaque, aortic sclerosis 46 (19) No
9 F 61 Pos. 3-vessel CAD, CABG 52 (22) No
10 M 47 Neg. 3-vessel CAD, PAD 312 (130) Yes
11 M 53 Neg. 2-vessel CAD, AC plaque, CABG 60 (25) No
12 M 60 Pos. Aortic sclerosis 62 (26) No
13 M 55 Neg. 3-vessel CAD, CABG 20 (8) No
14 M 79 Pos. CAD, ischemic stroke 64 (27) No
15 M 60 Pos. AC plaque, aortic sclerosis 7 (3) No
16 F 69 N.a. AC plaque, aortic sclerosis 19 (8) No
17 F 71 Pos. 3-vessel CAD, CABG 20 (8) No
18 M 57 Neg. CAD, CABG 14 (6) No
19 F 61 Pos. AC plaque, aortic sclerosis 42 (17) No
20 M 36 N.a. AC plaque, aortic sclerosis 65 (27) No
21 F 64 Neg. AC plaque, aortic sclerosis 7 (3) No
22 F 67 Pos. 3-vessel CAD, stenting 20 (8) No
23 M 67 Neg. 2-vessel CAD, AC plaque, CABG 36 (15) No
24 M 50 Pos. 3-vessel CAD, MI, resuscitation, stenting 20 (8) No
25 M 70 Neg. 3-vessel CAD, MI 58 (24) No
26 F 44 Pos. Primary prevention 118 (49) No
27 F 70 Pos. Aortic sclerosis 163 (68) Yes
28 M 63 Pos. 3-vessel CAD, MI, stroke 19 (8) No
29 F 42 Pos. Primary prevention 27 (11) No
30 M 66 Neg. Aortic sclerosis 19 (8) No
31 M 55 Pos. 2-vessel CAD, MI 20 (8) No
32 M 44 Pos. 2-vessel CAD, MI, stenting 255 (106) Yes
33 F 60 Neg. AC plaque, stroke NA NA
34 F 42 Pos. AC plaque 259 (108) Yes
35 F 53 Pos. 1-vessel CAD, MI 58 (24) No
36 F 70 Pos. 3-vessel CAD, MI 142 (59) No
37 M 48 Pos. Aortic sclerosis 144 (60) No
38 M 39 Pos. 3-vessel CAD, MI < 20 (< 8) No
AC — arteria carotis; ACI — arteria carotis interna; CABG — coronary artery bypass grafting; F — female; M — male; NA — not available;  
MI — myocardial infarction; neg. — negative; PAD — peripheral artery disease; pos. — positive
total, conventional therapy and PCSK9 inhibitors 
in combination led to a reduction of LDL-C levels 
of about 70% when compared to the therapy-naïve 
situation. Despite this potent reduction, only 
1 (50%) patient of the high risk group and 15 (42%) 
patients of the very high risk group reached target 
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Table 2. Low density lipoprotein cholesterol (LDL-C) levels under different lipid lowering treatment 
regimens. 
No. Previous  
medication
Escalation  
to PCSK9
LDL-0 
[mg/dL]
LDL-1 
[mg/dL]
Red.  
[%]
LDL-2 
[mg/dL]
Red.  
[%]
PCSK9  
inhibitor
LDL-C 
goal
1 Naïve Statin  
intolerance
197 197 0 91 54 Alirocumab 
75 mg
No
2 Atorvastatin 60 mg Intolerance to 
higher dose, 
ezetimibe  
intolerance
277 209 25  153  27 Alirocumab 
150 mg
No
3 Atorvastatin 20 mg, 
colesevelam
Intolerance to 
higher dose
180 163 9 124  24 Evolocumab 
140 mg
No
4 Fluvastatin 80 mg Statin intolerance, 
ezetimibe  
intolerance
204 110 46 20 81 Alirocumab 
75 mg
Yes
5 Pravastatin 40 mg, 
ezetimibe 10 mg
Statin intolerance 358 268 25 79 70 Alirocumab 
150 mg
No
6 Atorvastatin 40 mg, 
ezetimibe 10 mg
Intolerance to 
higher dose
NA 136 NA 50 63 Evolocumab 
140 mg
Yes
7 Atorvastatin 40 mg, 
colesevelam
Intolerance to 
higher dose
233 96 59 63 34 Alirocumab 
75 mg
Yes
8 Fluvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Statin  
intolerance
299 156 48 79 49 Evolocumab 
140 mg
No
9 Atorvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Maximum dose, 
missed target 
range
388 122 69 32 53 Evolocumab 
140 mg
Yes
10 Rosuvastatin 20 mg, 
ezetimibe 10 mg
Statin  
intolerance
245 112 54 34 70 Evolocumab 
140 mg
Yes
11 Atorvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Maximum dose, 
missed target 
range
NA 120 NA 21 83 Alirocumab 
75 mg
Yes
12 Atorvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Maximum dose, 
missed target 
range
258 154 40 35 87 Alirocumab 
150 mg
Yes
13 Ezetimibe 10 mg Statin  
intolerance
NA 150 NA 80 47 Alirocumab 
150 mg
No
14 Naïve Statin  
intolerance, 
ezetimibe  
intolerance
NA 141 NA 80 43 Alirocumab 
75 mg
No
15 Atovastatin 40 mg, 
ezetimibe 10 mg
Intolerance to 
higher dose
276 144 48 34 76 Evolocumab 
140 mg
Yes
16 Naïve Statin  
intolerance, 
ezetimibe  
intolerance
264 264 0 114 57 Alirocumab 
150 mg
No
17 Naïve Statin  
intolerance, 
ezetimibe  
intolerance
195 195 0 121 38 Alirocumab 
75 mg
No
18 Colesevelam Statin  
intolerance, 
ezetimibe  
intolerance
198 154 22 64 59 Evolocumab 
14 0mg
Yes
19 Rosuvastatin 40 mg, 
ezetimibe 10 mg
Maximum dose, 
missed target 
range
n.a. 168 NA 86 48 Alirocumab 
150 mg
No
www.cardiologyjournal.org 37
Michael Saborowski et al., PCSK9-inhibitors in a real world cohort
Table 2 (cont.). Low density lipoprotein cholesterol (LDL-C) levels under different lipid lowering  
treatment regimens. 
No. Previous  
medication
Escalation  
to PCSK9
LDL-0 
[mg/dL]
LDL-1 
[mg/dL]
Red.  
[%]
LDL-2 
[mg/dL]
Red.  
[%]
PCSK9  
inhibitor
LDL-C 
goal
20 Atorvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Maximum dose, 
missed target 
range
520 200 61 102 49 Evolocumab 
140 mg
No
21 Colesevelam, 
ezetimibe 10 mg
Statin  
intolerance
279 189 32 85 55 Evolocumab 
140 mg
No
22 Naïve Statin  
intolerance
NA 126 NA 39 69 Alirocumab 
150 mg
Yes
23 Colesevelam, 
ezetimibe 10 mg
Statin  
intolerance
212 120 43 81 32 Evolocumab 
140 mg
No
24 Naïve Statin intolerance, 
ezetimibe  
intolerance
NA 77 NA 38 51 Evolocumab 
140 mg
Yes
25 Naïve Statin intolerance, 
ezetimibe  
intolerance
207 196 5,3 114 42 Alirocumab 
150 mg
No
26 Simvastatin 40 mg, 
ezetimibe 10 mg
Maximum dose, 
missed target 
range
311 167 46 86 53 Alirocumab 
150 mg
Yes
27 Atorvastatin 40 mg, 
ezetimibe 10 mg
Maximum dose, 
missed target 
range
NA 127 NA 51 60 Alirocumab 
75 mg
Yes
28 Simvastatin 40 mg, 
ezetimibe 10 mg
Maximum dose, 
missed target 
range
287 178 38 82 54 Evolocumab 
140 mg
No
29 Naïve Statin  
intolerance
324 260 20 231 12 Evolocumab 
140 mg
No
30 Ezetimibe 10 mg Statin  
intolerance
251 251 0 99 60 Alirocumab 
75 mg
No
31 Atorvastatin 80 mg, 
Ezetimibe 10 mg
Maximum dose, 
missed target 
range
NA 152 NA Evolocumab 
140 mg
NA
32 Atorvastatin 40 mg, 
Ezetimibe 10 mg
Intolerance to 
higher dose
160 115 28.3 54 53 Evolocumab 
140 mg
Yes
33 Rosuvastatin 10 mg Intolerance to 
higher dose
NA 155 NA 81 48 Alirocumab 
150 mg
No
34 Atorvastatin 80 mg Ezetimibe  
intolerance
210 155 26 81 48 Alirocumab 
75 mg
No
35 Atorvastatin 80 mg, 
ezetimibe 10 mg,  
colesevelam
Maximum dose, 
missed target 
range
249 149 40 58 61 Evolocumab 
140 mg
Yes
36 Naïve Statin  
intolerance
208 208 NA  177 15 Evolocumab 
140 mg
No
37 Simvastatin 40 mg, 
ezetimibe 10
Maximum dose, 
missed target 
range
348 191 45 92 51 Evolocumab 
140 mg
No
38 Atorvastatin 40 mg Intolerance to 
higher dose
168 110 35 19 82 Evolocumab 
140 mg
Yes
LDL-0 — LDL-C levels before start of a lipid lowering therapy; LDL-1 — LDL-C values after reaching maximum tolerated dose with statins, 
ezetimibe or colesevelam; LDL-2 — LDL-C after addition of a PCSK9 inhibitor; NA — not available
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LDL-C levels. In addition, Lp(a) levels after initia-
tion of PCSK9 inhibitor treatment were also meas-
ured in patients with significantly elevated Lp(a) 
(> 150 nmol/L). Four out of these 5 patients 
showed a reduction of Lp(a) levels (average 25.4%) 
upon PCSK9 inhibitor treatment. One patient ex-
hibited a 31.3% increase of Lp(a) (Table 3). 
Six patients, all female, reported side ef-
fects of PCSK9 inhibitor treatment. All of these 
patients had also experienced side effects under 
their previous lipid-lowering regimen (e.g. mus-
cle pain). Three of these patients continued their 
medication despite these side effects. One female 
patient reacted with severe hypotension after 
injection of 140 mg evolocumab. After the second 
injection hypotension occurred again and led to 
hospitalization. Side effects, risks and benefits of 
this medication were discussed with patients and 
a decision was reached to switch to alirocumab 
in a reduced dosage (75 mg) every 2 weeks. This 
medication was well tolerated. Two other female 
patients were also switched to alirocumab due to 
mild side effects such as muscle pain. 
PCSK9 inhibition is not only a new pharma-
cological approach scientifically but also a new 
approach for patients as well. Being used to taking 
pills, patients must now inject their medication 
once or twice a month. For monitoring therapy 
adherence, a simple questionnaire is sent to all 
38 patients (Supplemental Figure 1). Responses 
from 31 patients were received. Results showed 
not only a long individual history of the disease 
with an average duration of 19 years but also that 
nearly all patients had tried different lipid lower-
ing drugs because of significant side effects. Over 
90% of the patients had tried multiple statins and 
had had to switch medications in the past (Fig. 2).
Concerning therapy adherence, 27 of 31 pa-
tients (87%), that returned the anonymous ques-
tionnaire stated to have used PCSK9 inhibitors 
on a regular basis as prescribed. Interestingly, 
the remaining 4 patients reported side effects 
to PCSK9 inhibitors. All of these patients had 
previously reported side effects to statins as 
well (Fig. 2). 
Discussion
Cardiovascular disease remains among the 
most common causes of death worldwide, demon-
strating the need for improved treatment regimens 
to reduce the incidence and progression of CAD. 
LDL-C levels have been shown to be one of the 
Figure 1. Average low density lipoprotein cholesterol 
(LDL-C) levels under different lipid lowering treatment 
regimens; LDL-0 — LDL-C levels before begin of a li-
pid lowering therapy (naïve); LDL-1 — LDL-C values 
after reaching maximum tolerated dose with statins, 
ezetimibe or colesevelam (without PCSK9); LDL-2 — 
LDL-C after addition of a PCSK9 inhibitor (with); df — 
degree of freedom; CI — confidence interval.
Table 3. Comparison of lipoprotein(a) [Lp(a)] before and after initiation of PCSK9 inhibition in 5 patients with 
significant elevation of Lp(a). Patient numbers correspond to patient from Table 1 and Table 2.
Patient no. Sex Lp(a) before PSCK9  
[nmol/L (mg/dL)]
Lp(a) after PCSK9 
[nmol/L (mg/dL)]
Difference 
[%]
2 Female 288 (120) 198 (83) –31.25
10 Male 312 (130) 259 (108) –16.70
27 Female 163 (68) 214 (89) +31.30
32 Male 255 (107) 189 (78) –25.80
34 Female 259 (108) 187 (77) –27.80
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Figure 2. A questionnaire sent to all 38 patients was returned by 31 patients; A. Age of patients; B. Percent of patients 
that suffered from side effects of other lipid lowering drugs before PCSK9 inhibitor therapy; C. Percent of patients that 
needed a switch of lipid lowering therapy in the past; D. Percent of patients that knew why their physician switched 
the medication to a PCSK9 inhibitor; E. Percent of patients that injected the medication as prescribed; F. Percent of 
patients that felt safe using a PCSK9. 
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main therapeutic parameters in the treatment and 
prevention of atherosclerosis and CAD. 
Herein is data reported from patients treated 
with PCSK9 inhibitors outside of clinical trials in 
a real-world cohort of 38 patients. All but two of 
these patients exhibited a very high-risk profile 
for CAD with a recommended LDL-C target range 
of < 70 mg/dL. These patients reported that they 
had not only suffered from high LDL-C levels 
for an average of 19 years but also experienced 
myocardial infarction and/or other CVD. They 
had not been able to reach their specific LDL-C 
target range although their conventional therapy 
regimens reduced LDL-C of on average about 38%. 
This cohort of patients had very high therapy naïve 
starting LDL-C levels (average 260 mg/dL), illus-
trating the difficulties medical doctors face when 
aiming to reach LDL-C targets with conventional 
therapy. In particular, side effects such as muscular 
and articular pain frequently prevented further 
dose escalation. With the help of an anonymous 
questionnaire the study was also able to show that 
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the vast majority of patients had to switch their 
medication of statins and ezetimibe based therapies 
due to recurrent side effects. Most of the patients 
that initially used statins had to change to less 
potent statins like fluvastatin during the course 
of the disease. In addition to the high starting, 
therapy-naïve LDL-C, the frequent side effects of 
potent statins, the failure to reach the maximum 
dose and switching to less potent statins played 
a major role in the low frequency of patients that 
reached the target LDL-C levels in this cohort.
After the addition of PCSK9 inhibitors, 16 of 
38 patients achieved target LDL-C levels. These 
results illustrate not only the effectiveness of 
PCSK9 inhibitors but also the importance of con-
ventional therapy and the need to maximize its 
effect. It is advisable to titrate the dose of statins 
to the maximum tolerated level. Nevertheless, the 
maximum allowed dosage of any prescribed statin 
was reached in less than half of these patients. In 
addition, statins should be combined with ezetimibe 
and colesevelam to increase LDL-C reduction prior 
to initiation of PCSK9 inhibitor therapy. 
 In the present cohort 5 patients were detected 
showing elevated levels of Lp(a). Four of these 
patients showed a reduction on average of 25% in 
Lp(a) levels. Surprisingly, 1 patient exhibited an 
increase of about 31%, showing that the effects 
PCSK inhibition on Lp(a) levels are not uniform 
among patients. 
From the questionnaires it was learned that 
therapy adherence to PCSK9 inhibitors was rela-
tively high as compared to conventional therapy. 
Despite the fact that 6 patients reported side effects 
under PCSK9 inhibitor therapy, none of them had to 
terminate treatment and only one patient switched 
to a reduced dose of alirocumab. Interestingly, all 
patients that had side effects from PCSK9 inhibiting 
therapy were female. Furthermore, only 12% of total 
patients admitted to not injecting the inhibitor on 
a regular basis. Interestingly, these patients all had 
experienced side effects on statin based therapies 
before starting evolocumab or alirocumab. There-
fore, to reduce the risk of incompliance due to the 
fear of side effects, it was suggested that patients 
with previous experience of side effects should be 
particularly well informed. In general, in-depth 
information about the medication and close supervi-
sion by the prescribing medical doctor is advisable.
Concerning safety, one major side effect was 
seen (severe hypotension with the need of hospi-
talization) which prompted us to change medication. 
Side effects, risks and benefits of this medication was 
discussed with our patient and a decision was made 
to switch to alirocumab in a reduced dosage (75 mg) 
every 2 weeks. The new therapy was well tolerated.
This study emphasizes that initiation of 
PCSK9 inhibitor treatment should be carefully 
checked. Furthermore, risks and benefits of this 
therapy needs to be discussed in depth with pa-
tients. In addition, changing between evolocumab 
and alirocumab in the case of severe side effects 
may also be an option. The present results support 
ESC/EAS consensus statement [12] that suggests 
that the use of a PCSK9 inhibitor is worthwhile 
in patients with a LDL-C level > 140 mg/dL or 
a realistic reduction of LDL-C of about 50%. Ge-
netic testing should also be encouraged for familial 
hypercholesterolemia by assessing LDL receptor 
mutations. The present results show that the 
chance of detecting a mutation in this subgroup of 
cardiovascular patients is very high. 
In summary, results document a highly effi-
cient lowering of LDL-C with PCSK9 inhibitors in 
a real-world cohort. Furthermore, they document 
a satisfactory therapy adherence to this new medi-
cation outside of clinical trials. Nevertheless, target 
levels were not achieved in the majority of patients 
even after the addition of a PCSK9. Conventional 
statin-based therapy is still needed in combination 
with PCSK9 inhibitor therapy. Identification of 
individuals at highest risk of an (recurrent) event 
is paramount, as they will potentially benefit to the 
greatest degree.
Conclusions
PCSK9-inhibitors were well tolerated in a co-
hort of patients at high or very high cardiovascular 
risk and therapy adherence was overall satisfactory. 
Several patients who were not able to tolerate 
high doses of previous treatment regimens and 
did not reach target LDL-C levels successfully 
achieved recommended LDL-C treatment goals on 
PCSK9-inhibitors. Lowering of Lp(a) upon PCSK9 
inhibition might be an additional benefit, but was 
not achieved in all patients. It is recommended that 
risks and benefits of side effects and costs be taken 
into account when prescribing PCSK9-inhibitors. 
Furthermore, switching between alirocumab and 
evolocumab in the case of severe side effects may 
be an option, but further research is needed.
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